InvestmentUpdated on 5 December 2024
Anticipating a Series A round in Q2 2025
About
We value building trust with investors, having regular conversations, laying out the plan, reporting on milestones and raising capital when most relevant to take Limula to the next chapter. We have closed a Seed round of CHF/€ 7.2m in May 2024, looking at closing a Series A in Q3 2025 to establish a commercial team when the alpha product is ready to ship to committed customers.
Stage
- Early stage.
Applies to
- Biotech and Pharma